|
| Press Releases |
|
 |
|
| Tuesday, June 21, 2022 |
|
|
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
| Wednesday, June 15, 2022 |
|
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, June 9, 2022 |
|
|
SinoMab Announces IND Application for SN1011 Accepted by NMPA CDE |
| SinoMab BioScience Limited ("SinoMab"; 3681.HK), a Hong Kong-based biopharmaceutical company, an Investigational New Drug application (IND, for neuromyelitis optica spectrum disorder (NMOSD)) for SN1011 has been filed with and accepted by the Center for Drug Evaluation (the CDE) of the National Medical Products Administration of China (NMPA). more info >> |
|
| Wednesday, April 20, 2022 |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
| Monday, March 14, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, February 17, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Monday, February 7, 2022 |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022, more info >> |
|
| Tuesday, January 11, 2022 |
|
|
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Tuesday, November 30, 2021 |
|
|
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03 |
| SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, November 26, 2021 |
|
|
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health |
| SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Radisson Announces Additional High-Grade Drill Results and Further Extends New Mineralization Beneath the Historic O'Brien Gold Mine
Jan 6, 2026 20:00 HKT/SGT
|
|
|
Hong Kong Toys & Games Fair leads market innovation, debut 'Pop & Play' pavilion opens to industry and public
Jan 6, 2026 18:50 HKT/SGT
|
|
|
CTF Life Amplifies Ecosystem Synergy
Jan 6, 2026 15:35 HKT/SGT
|
|
|
Mitsubishi Motors to Celebrate "Delica Festival" with Custom Versions of Delica D:5 and Delica Mini at Tokyo Auto Salon 2026
Jan 6, 2026 16:25 JST
|
|
|
Mitsubishi Motors Launches the Xforce in Taiwan
Jan 6, 2026 14:42 JST
|
|
|
">
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
Jan 6, 2026 10:43 JST
|
|
|
Asian Financial Forum kicks off 2026 as region's first major event of 2026 
Jan 6, 2026 04:41 HKT/SGT
|
|
|
Notice on the Establishment of a Special Subsidiary
Jan 5, 2026 21:00 HKT/SGT
|
|
|
TANAKA Announces Executive Appointment
Jan 5, 2026 21:00 HKT/SGT
|
|
|
Asian Financial Forum kicks off 2026 as region's first major event of 2026
Jan 5, 2026 15:39 HKT/SGT
|
|
|
Alpha Growth plc: Alpha Longevity Management Ltd Expands Global Platform with Launch of Alpha Alternative Global Fund and Strengthening of Executive Leadership Team
Jan 5, 2026 16:00 JST
|
|
|
The Tampere city region chose Fujitsu to deliver and develop the area's ICT services
Jan 5, 2026 15:23 JST
|
|
|
AVIA's Coalition Against Piracy Secures New Singapore Court Order Blocking 53 Illegal Streaming Domains
Jan 5, 2026 13:35 HKT/SGT
|
|
|
As Geekplus approaches the unlocking, the major cornerstone investors such as Xiongan Fund commit to holding their shares
Jan 5, 2026 09:46 HKT/SGT
|
|
|
Hong Kong Tech Exhibits Immense Potential at CES 2026 with 61 Tech Companies Ready for Global Markets, Largest-ever Hong Kong Tech Pavilion features 3 Innovation Award-winning game-changers showcasing immense potential to scale
Jan 4, 2026 12:03 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
